Proton versus photon therapy for esophageal cancer - A trimodality strategy

Radiother Oncol. 2024 Jan;190:109980. doi: 10.1016/j.radonc.2023.109980. Epub 2023 Nov 5. A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.

Mortensen HR(1), Populaire P(2), Hoffmann L(3), Moeller DS(3), Appelt A(4), Nafteux P(5), Muijs CT(6), Grau C(7), Hawkins MA(8), Troost EGC(9), Defraene G(10), Canters R(11), Clarke CS(12), Weber DC(13), Korevaar EW(6), Haustermans K(2), Nordsmark M(14), Gebski V(15), Achiam MP(16), Markar SR(17), Radhakrishna G(18), Berbee M(19), Scartoni D(20), Orlandi E(21), Doyen J(22), Gregoire V(23), Crehange G(24), Langendijk J(25), Lorgelly P(26), Blommenstein HM(27), Byskov CS(28), Ehmsen ML(7), Jensen MF(7), Freixas GV(29), Bütof R(30); PROTECT consortium.

Author information: (1)Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark. (2)University Hospitals Leuven, Department of Radiation Oncology, Belgium; KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium. (3)Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark. (4)University of Leeds, Leeds, UK. (5)University Hospitals Leuven, Department of Thoracic Surgery, Belgium. (6)Department of Radiation Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. (7)Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark. (8)Department of Medical Physics and Biomedical Engineering, University College London, London, UK. (9)Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany. (10)KU Leuven- University of Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, Leuven, Belgium. (11)Department of Radiation Oncology (Maastro), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, the Netherlands. (12)Research Dept. of Primary Care and Population Health, University College London, London, UK. (13)Center for Proton Therapy, Paul Scherrer Institut, Villigen, Switzerland; Radiation Oncology Department, University Hospital Zurich, Zurich, Switzerland. (14)Department of Oncology and Medical Physics, Aarhus University Hospital, Aarhus, Denmark. (15)NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. (16)Dept. Surgery and Transplantation, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. (17)Department of General Surgery, Oxford University Hospitals, Oxford, UK; Nuffield Department of Surgery, University of Oxford, Oxford, UK. (18)The Christie, Manchester, United Kingdom. (19)Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands. (20)Proton Therapy Center, Azienda Provinciale per i Servizi Sanitari, Trento, Italy. (21)National Center for Oncological Hadrontherapy (CNAO), Radiation Oncology Clinical Department, Pavia, Italy. (22)Centre Antoine Lacassagne, Nice, France. (23)Centre Léon Bérard, 28 rue Laennec, Lyon 69373 Cedex 08, France. (24)PSL Research University, RadiationOncology Department, Institut Curie, Paris/Orsay, France. (25)Department of Radiation Oncology, UniversityMedicalCentreGroningen, Groningen, The Netherlands. (26)University of Auckland, Waipara Taumata Rau, Auckland, New Zealand. (27)Erasmus School of Health Policy and Management, Erasmus University Rotterdam, P.O. Box 1738, Rotterdam, 3000 DR, The Netherlands; Erasmus Centre for Health Economics Rotterdam, Erasmus University, Rotterdam, The Netherlands. (28)Department of Oncology and Medical physics, Aarhus University Hospital, Aarhus, Denmark. (29)Maastro Proton Therapy, Department of Radiation Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands. (30)Department of Radiotherapy and Radiation Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden and OncoRay - National Center for Radiation Research in Oncology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, and Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiooncology - OncoRay Helmholtz-Zentrum Dresden-Rossendorf, Germany.

DOI: 10.1016/j.radonc.2023.109980 PMID: 37935284 [Indexed for MEDLINE]

Conflict of interest statement: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Hanna Rahbek Mortensen is Co-chair of Patient Involvement Work Package in PROTECT.].